15:35 uur 09-02-2016

ADC Therapeutics dient eerste dosis toe voor onderzoek naar ADCT-301 tegen acute myeloïde leukemie

LAUSANNE, Switzerland & LONDON & MURRAY HILL,N.J.–(BUSINESS WIRE)– ADC Therapeutics SA (ADCT), het bedrijf in ontwikkeling van oncologische medicijnen, heeft bekendgemaakt dat het de eerste dosis voor een fase 1-onderzoek naar zijn antistof-medicijnconjugaat tegen acute myeloïde leukemie heeft toegediend aan een patiënt.

Het in twee fases opgedeelde open-labelonderzoek is gericht op een beoordeling van de verdraagbaarheid, veiligheid, farmacokinetiek en activiteit van ADCT-301 bij patiënten met teruggekeerde of hardnekkige, CD-25-positieve AML. Aan de eerste fase, waarin de dosis wordt opgevoerd, doen dertig patiënten in tien Amerikaanse klinische vestigingen mee. Het doel is het vaststellen van de aanbevolen dosis van ADCT-301 voor de tweede fase. In deze tweede fase breidt het onderzoek zich uit met nog eens dertig deelnemers uit het Verenigd Koninkrijk en andere Europese landen.


ADC Therapeutics Doses First Patient in Phase I Trial of ADCT-301 Trial in Acute Myeloid Leukemia

LAUSANNE, Switzerland & LONDON & MURRAY HILL,N.J.–(BUSINESS WIRE)– ADC Therapeutics SA (ADCT), the oncology drug development company, announces that the first patient has been dosed in a Phase I trial to evaluate its lead antibody drug conjugate (ADC) ADCT-301 in Acute Myeloid Leukemia (AML).

The two stage, Phase l open-label trial will evaluate the tolerability, safety, pharmacokinetics and activity of ADCT-301 in patients with relapsed or refractory CD-25 positive AML. The initial dose escalation phase will recruit up to 30 patients at ten clinical sites across the US and will seek to determine the recommended dose of ADCT-301 for the second stage. The second stage, which will begin once an appropriate dose is identified, will be expanded into the UK and Europe with the recruitment of up to 30 additional patients.

ADCT-301 is composed of HuMax ®-TAC, a monoclonal antibody directed against CD25 (the alpha chain of the IL-2 receptor) conjugated to ADCT’s highly potent proprietary pyrrolobenzodiazepine (PBD) dimer. In preclinical in vivo models, ADCT-301 exhibited strong dose-dependent anti-tumor activity against CD25-positive cell lines at single low doses.

Professor Martin Tallman, Principle Investigator of the trial and Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center, New York, said: “Acute myeloid leukemia is the most common leukemia in the US adult population and the prognosis is poor. Patients expressing CD25 on their leukemia cells have a particularly poor prognosis.

ADCT-301 has shown promise in in vivo studies and we believe that this important trial could help us to improve patient outcomes.”

Dr Chris Martin, CEO of ADC Therapeutics, added: “Dosing the first patient in this trial with ADCT-301 is an important milestone for the Company. We look forward to the progress of this trial over the coming year and to accelerating the clinical development of our ADC pipeline.”

ADC Therapeutics currently has two PBD-based ADCs in four clinical trials, with four other ADCs in late preclinical development and further ADCs in research.


Notes to Editors

About ADC Therapeutics ( www.adctherapeutics.com )

ADC Therapeutics SA (ADCT) is an oncology drug development company that specializes in the development of proprietary ADCs targeting major solid and hematological cancers. The Company’s ADCs are highly targeted drug constructs which combine monoclonal antibodies specific to surface antigens present on particular tumor cells with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads. The Company has access to warhead and linker chemistries via agreements with Spirogen (a wholly-owned subsidiary of AstraZeneca’s MedImmune). It is progressing eleven ADC programs, one of these under a joint development agreement with MedImmune. During 2015 ADCT-301 and ADCT-402 entered Phase I for lymphoma and leukemia. ADC Therapeutics has its head office in Lausanne, Switzerland and has its R&D laboratories in London, UK, its clinical development team in New Jersey, USA, and its manufacturing team based in San Francisco, USA.


Instinctif Partners
Sue Charles / Gemma Howe
T: +44 (0)20 7866 7860
adctherapeutics@instinctif.com< br/>or
Instinctif Partners – Switzerland
Kirsten Duelli
T: +41 (0) 44 280 11 86

Check out our twitter: @NewsNovumpr